153 related articles for article (PubMed ID: 35676678)
1. Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.
Jeong SH; Han JH; Jeong CW; Kim HH; Kwak C; Yuk HD; Ku JH
BMC Cancer; 2022 Jun; 22(1):631. PubMed ID: 35676678
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors.
Lee K; Jeong SH; Yoo SH; Ku JH
Investig Clin Urol; 2022 Jan; 63(1):14-20. PubMed ID: 34983118
[TBL] [Abstract][Full Text] [Related]
3. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
4. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
Sylvester RJ; Oosterlinck W; Holmang S; Sydes MR; Birtle A; Gudjonsson S; De Nunzio C; Okamura K; Kaasinen E; Solsona E; Ali-El-Dein B; Tatar CA; Inman BA; N'Dow J; Oddens JR; Babjuk M
Eur Urol; 2016 Feb; 69(2):231-44. PubMed ID: 26091833
[TBL] [Abstract][Full Text] [Related]
5. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center.
Lazica DA; Roth S; Brandt AS; Böttcher S; Mathers MJ; Ubrig B
Urol Int; 2014; 92(2):131-5. PubMed ID: 23988813
[TBL] [Abstract][Full Text] [Related]
6. The need for re-TUR of the bladder in non-muscle invasive bladder cancer: risk factors of tumor persistence in re-TUR specimens.
Husillos Alonso A; Rodríguez Fernández E; Herranz Amo F; López López E; Aragón Chamizo J; Ramírez Martínez D; Durán Merino R; Hernández Fernández C
Minerva Urol Nefrol; 2014 Dec; 66(4):233-40. PubMed ID: 25531192
[TBL] [Abstract][Full Text] [Related]
7. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
8. [T1 high-grade bladder cancer - value of second operation with prognostuic parameters of first operation: analysis of 167 cases].
Lazica DA; Böttcher S; Degener S; von Rundstedt FC; Brandt AS; Roth S; Störkel S; Mathers MJ
Aktuelle Urol; 2013 Mar; 44(2):124-8. PubMed ID: 23580383
[TBL] [Abstract][Full Text] [Related]
9. Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
Laukhtina E; Moschini M; Krajewski W; Teoh JY; Ploussard G; Soria F; Roghmann F; Muenker MA; Roumiguie M; Alvarez-Maestro M; Misrai V; Antonelli A; Tafuri A; Simone G; Mastroianni R; Zhao H; Rahota RG; D'Andrea D; Mori K; Albisinni S; Karakiewicz PI; Fajkovic H; Enikeev D; Montorsi F; Shariat SF; Pradere B;
BJU Int; 2023 May; 131(5):571-580. PubMed ID: 36134575
[TBL] [Abstract][Full Text] [Related]
10. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
May M; Helke C; Nitzke T; Vogler H; Hoschke B
Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
[TBL] [Abstract][Full Text] [Related]
11. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.
Hermann GG; Mogensen K; Carlsson S; Marcussen N; Duun S
BJU Int; 2011 Oct; 108(8 Pt 2):E297-303. PubMed ID: 21414125
[TBL] [Abstract][Full Text] [Related]
12. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection.
Deng N; Chen JX; Chen LW; Qiu SP; Li XF; Wang DH
Chin Med J (Engl); 2012 Oct; 125(20):3681-6. PubMed ID: 23075724
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer.
Sauer R; Birkenhake S; Kühn R; Wittekind C; Schrott KM; Martus P
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):121-7. PubMed ID: 9422567
[TBL] [Abstract][Full Text] [Related]
14. Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Contieri R; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
Int Urol Nephrol; 2024 Apr; 56(4):1323-1333. PubMed ID: 37980689
[TBL] [Abstract][Full Text] [Related]
15. Positive urine cytology and carcinoma in situ prior to second transurethral resection of the bladder correlate with positive second resection histology and the need for subsequent cystectomy.
Lodde M; Mayr R; Martini T; Comploj E; Palermo S; Trenti E; Hanspeter E; Fritsche HM; Mian C; Pycha A
World J Urol; 2012 Dec; 30(6):841-6. PubMed ID: 23143733
[TBL] [Abstract][Full Text] [Related]
16. Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis.
Daryanto B; Purnomo AF; Seputra KP; Budaya TN
Med Arch; 2022 Jun; 76(3):198-201. PubMed ID: 36200115
[TBL] [Abstract][Full Text] [Related]
17. Narrow-band imaging (NBI) and white light (WLI) transurethral resection of the bladder in the treatment of non-muscle-invasive bladder cancer.
Montanari E; de la Rosette J; Longo F; Del Nero A; Laguna P
Arch Ital Urol Androl; 2012 Dec; 84(4):179-83. PubMed ID: 23427740
[TBL] [Abstract][Full Text] [Related]
18. [Radical cystectomy in the treatment of bladder cancer always in due time?].
May M; Braun KP; Richter W; Helke C; Vogler H; Hoschke B; Siegsmund M
Urologe A; 2007 Aug; 46(8):913-9. PubMed ID: 17676301
[TBL] [Abstract][Full Text] [Related]
19. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
[TBL] [Abstract][Full Text] [Related]
20. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
